Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 137.27M | 145.24M | 146.03M | 157.07M | 209.82M | 108.08M |
Gross Profit | 132.29M | 139.23M | 141.09M | 151.86M | 206.42M | 105.38M |
EBITDA | -76.92M | -38.60M | -118.42M | -139.31M | -96.98M | -167.85M |
Net Income | -123.57M | -76.42M | -143.10M | -165.29M | -124.09M | -196.27M |
Balance Sheet | ||||||
Total Assets | 104.88M | 164.42M | 240.44M | 358.17M | 305.31M | 313.05M |
Cash, Cash Equivalents and Short-Term Investments | 38.73M | 108.71M | 191.44M | 277.97M | 228.62M | 249.24M |
Total Debt | 94.80M | 194.52M | 177.02M | 179.07M | 180.58M | 131.13M |
Total Liabilities | 343.81M | 350.44M | 376.64M | 374.83M | 384.98M | 262.50M |
Stockholders Equity | -238.93M | -186.02M | -136.21M | -16.66M | -79.67M | 50.55M |
Cash Flow | ||||||
Free Cash Flow | -102.89M | -127.63M | -92.72M | -149.67M | -112.83M | -160.38M |
Operating Cash Flow | -102.94M | -127.49M | -92.72M | -149.55M | -107.12M | -160.23M |
Investing Cash Flow | 55.84M | 95.47M | 7.94M | -104.26M | 141.84M | -53.69M |
Financing Cash Flow | 1.04M | 41.65M | 1.12M | 193.74M | 73.65M | 172.08M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $61.65M | ― | 41.08% | ― | -5.77% | -22.78% | |
51 Neutral | $7.90B | -0.33 | -41.69% | 2.23% | 23.45% | -1.99% | |
49 Neutral | $114.49M | ― | -58.89% | ― | ― | ― | |
48 Neutral | $59.45M | ― | -100.55% | ― | -100.00% | -22.09% | |
44 Neutral | $84.30M | 0.66 | -207.22% | ― | 5721.31% | -671.01% | |
40 Underperform | $39.36M | ― | -85.69% | ― | ― | 10.04% | |
― | $30.64M | ― | ― | ― | ― |
Karyopharm Therapeutics has been in discussions with potential investors to explore financing options to extend its cash runway, but no transaction has been finalized. The company is evaluating strategic alternatives, including potential mergers or sales, to maximize shareholder value. Additionally, Karyopharm is reducing its workforce by 20% to manage operating expenses, while continuing to focus on its commercial and clinical efforts in multiple myeloma and myelofibrosis. The company reported a net product revenue of $21.1 million in the first quarter of 2025, with a total revenue of $30 million, despite being impacted by increased returns of expired products.